H
Hossein Baharvand
Researcher at University of Science and Culture
Publications - 487
Citations - 20462
Hossein Baharvand is an academic researcher from University of Science and Culture. The author has contributed to research in topics: Embryonic stem cell & Stem cell. The author has an hindex of 56, co-authored 454 publications receiving 15081 citations. Previous affiliations of Hossein Baharvand include Avicenna Research Institute & Royan Institute.
Papers
More filters
Journal ArticleDOI
Generation of insulin‐secreting cells from human embryonic stem cells
TL;DR: The results showed that hESC have the ability to transcribe and process insulin, but further improvements of the current method are required to generate a sufficient source of true β cells for the treatment of diabetes mellitus.
Journal ArticleDOI
Proteomic signature of human embryonic stem cells.
TL;DR: This study represents the first proteomic dataset for hESC and provides a better insight into the biology of hESc.
Journal ArticleDOI
Safety analysis and improved cardiac function following local autologous transplantation of CD133(+) enriched bone marrow cells after myocardial infarction.
Hossein Ahmadi,Hossein Baharvand,Saeed Kazemi Ashtiani,Massoud Soleimani,Hakimeh Sadeghian,Jalil Madjd Ardekani,Narges Zare Mehrjerdi,Azam Kouhkan,Mehrnaz Namiri,Manouchehr Madani-Civi,Fatemeh Fattahi,Abdolhossein Shahverdi,Ahmad Vosough Dizaji +12 more
TL;DR: In patients with recent myocardial infarction, transplantation of CD133(+) cells to the peri-infarct zone during CABG surgery is feasible and safe, with no evidence of early or late adverse events.
Journal ArticleDOI
Culture condition difference for establishment of new embryonic stem cell lines from the C57BL/6 and BALB/c mouse strains.
TL;DR: The production of new ES cell lines from blastocysts recovered from the C57BL/6 and BALB/c mouse strains are described by changing the concentration of leukemia inhibitory factor (LIF) and primary culture conditions and indicate that ES cells from inbred strains can be isolated using commercially available reagents.
Journal ArticleDOI
Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies
TL;DR: A series of technological advances in all aspects of hPSC-based therapeutic product manufacturing including clinical grade cell line development, large-scale banking, upstream processing, downstream processing, and quality assessment of final cell therapeutic products that have brought hPSCs closer to clinical application and commercial cGMP manufacturing are highlighted.